Live Breaking News & Updates on Bharat Immunologicals Biologicals Corporation

Stay updated with breaking news from Bharat immunologicals biologicals corporation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

What pharma PSUs and government vaccine makers can and cannot do in the uphill battle against Covid-19

While government-owned pharma companies are ailing from years of neglect, some have rolled up their sleeves and joined Indias uphill battle against Covid, with plans to manufacture drugs that are used for treatment of Covid-19 patients or to produce vaccines that can shield people from the dreaded SARS-CoV-2 virus. ....

India General , Uttar Pradesh , Indian Immunologicals , Yashwant Gharpure , Haffkine Bio , Rk Anand Kumar , Nirja Saraf , Karnataka Antibiotics Ltd , National Dairy Development Board , Indian Immunologicals Ltd , Bharat Immunologicals Biologicals Corporation , Indian Drugs Pharmaceuticals Ltd , Corporation Ltd , Haffkine Institute , Sher Shah Suri , Old Grand Trunk Road , Bharat Immunologicals , Biologicals Corporation , Antibiotics Ltd , Bharat Biotech , Haffkine Bio Pharmaceutical Corporation Ltd , Central Public Sector Enterprise , Hindustan Antibiotics , Bengal Chemicals , Indian Drugs , Pharmaceuticals Ltd ,

Vaccinating the World is a Globally Integrated Enterprise

Many presume that vaccines produced by the Serum Institute of India (SII) are “Indian vaccines” by default. Covishield, the mainstay of India’s vaccination programme used in more than 85% of India’s inoculations, is the result of a mutually beneficial international collaboration. At least half of the doses SII produces are paid for by other countries and global platforms, but manufactured in India. The deadly second wave created an unforeseen emergency and disrupted India’s role as a global supplier of vaccines.
A recent analysis of company filings by the top four global vaccine manufacturers found that 90% all the vaccines produced in 2021 Q1 in the United States (US) and Europe were administered on populations within North America and Europe. Even in Q2, the situation is going to be the same. This brings to the front the importance of creating and expanding vaccine production capacity in the developing world. ....

South Africa , United States , United Kingdom , Vasudhaiva Kutumbakam , Indian Immunologicals Ltd , Bharat Immunologicals Biologicals Corporation , European Union , Gamaleya Research Institute , World Trade Organisation , Serum Institute Of India , Haffkine Biopharmaceutical Corporation , Serum Institute , North America , Defense Production Act , Compulsory Licenses , Bharat Biotech , Bharat Immunologicals , Biologicals Corporation , Covid Vaccine , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , வசுடைவா குடும்பகம் , ஐரோப்பிய தொழிற்சங்கம் , உலகம் வர்த்தகம் ஆர்கநைஸேஶந் , சீரம் நிறுவனம் ஆஃப் இந்தியா , சீரம் நிறுவனம் ,

Patent Waiver the New Pandemic Normal & India's Key Role in Emerging Global Consensus

Patent Waiver the New Pandemic Normal & India’s Key Role in Emerging Global Consensus
News18
1 day ago
Oommen C Kurian
© Provided by News18
Patent Waiver the New Pandemic Normal & India’s Key Role in Emerging Global Consensus
Earlier this year, stark inequities of global vaccine distribution, where limited supplies of COVID vaccine doses are mopped up by richer countries had forced the WHO chief to warn that the world was on the brink of a “catastrophic moral failure”. Lack of access to COVID-19 vaccines is now playing out across the world in terms of daily deaths spiralling out of control in relatively poorer countries, while vaccination efforts have resulted in significant reduction of deaths in the richer countries (Graph 1). The upper middle-income countries have also seen daily deaths plateau and start declining, albeit with a time lag, in tandem with global vaccine distribution statistics. There is dawning realisation tha ....

South Africa , United Kingdom , Olumiant Baricitinib , Vasudhaiva Kutumbakam , Eli Lilly , Oommenc Kurian , Indian Immunologicals Ltd , Senior Fellow Head Of Health Initiative , Bharat Immunologicals Biologicals Corporation , European Union , Technology Access Pool , Gates Foundation , World Trade Organisation , Serum Institute Of India , Haffkine Biopharmaceutical Corporation , Patent Waiver , New Pandemic Normal , Key Role , Emerging Global , Emerging Global Consensus , Compulsory Licenses , Navigate Global Pharma , Serum Institute , Timely Tech , Access Pool , With Indian ,

IIL confident of Covaxin rollout by August - The Hindu BusinessLine

IIL confident of Covaxin rollout by August
April 20, 2021
Company looks to start rolling out vaccine batches from July-August 2021
With its expertise in rabies vaccine production using the vero cell platform, public sector vaccine-maker Indian Immunologicals Ltd (IIL), an arm of the National Dairy Development Board (NDDB), is confident of starting Covaxin production by July/August as this vaccine uses the same technology, a top company official said.
The Centre is looking to accelerate production of the indigenous vaccine and has roped in IIL, Bharat Immunologicals & Biologicals Corporation (BIBCOL) and Haffkine Biopharmaceutical Corporation to collectively provide 10-15 million doses a month by August-September. ....

National Dairy Development Board , Indian Immunologicals Ltd , Bharat Immunologicals Biologicals Corporation , Haffkine Biopharmaceutical Corporation , Bharat Immunologicals , Biologicals Corporation , Bharat Biotech , Whole Virion Inactivated Vero Cell , தேசிய பால் வளர்ச்சி பலகை , உயிரியல் நிறுவனம் , பாரத் பயோடெக் ,

Govt moves to step-up Covaxin production - The Hindu BusinessLine

Govt moves to step-up Covaxin production
April 16, 2021
×
Ropes in 3 govt units, funds upgrade of Bharat Bio facility to raise monthly output to 10 cr doses by Sept
The Government has unveiled a plan to expand the manufacture of indigenous vaccine, Covaxin. The aim is to make 10 crore doses a month, by September.
The plan involves upgrading Hyderabad-based Bharat Biotech Ltd, which produces Covaxin, besides building-up the production capacities of public sector manufacturers Haffkine Biopharmaceutical Corp, Indian Immunologicals Ltd, and Bharat Immunologicals & Biologicals Corporation with infrastructure and technology.
The current production capacity will be doubled by May-June and then increased 6-7 fold by July-August. Thta is, production will be stepped up from 1 crore doses in April to 6-7 crore vials per month in July-August. It is likely to reach nearly 10 crore doses per month by September under the government’s Mission Covid Suraksha, the ....

Haffkine Biopharma , Bharat Immunologicals , National Dairy Development Board , Indian Immunologicals Ltd , Mission Covid Suraksha , Biologicals Ltd , Health Ministry , Department Of Biotechnology , Haffkine Biopharmaceutical Corp , Bharat Immunologicals Biologicals Corporation , Bharat Biotech Ltd , Hyderabad Based Bharat Biotech Ltd , Biologicals Corporation , Bharat Biotech , Hyderabad Based Indian Immunologicals Ltd , Bulandshahr Based Bharat Immunologicals , தேசிய பால் வளர்ச்சி பலகை , உயிரியல் லிமிடெட் , ஆரோக்கியம் அமைச்சகம் , துறை ஆஃப் உயிரி தொழில்நுட்பவியல் , பாரத் பயோடெக் லிமிடெட் , ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் லிமிடெட் , உயிரியல் நிறுவனம் , பாரத் பயோடெக் ,